![Caprico Biotechnologies 104025 CD33 PE Antibody, Clone WM53, Mouse IgG1,k, 100 Tests/Unit - 55-833LB | Genesee Scientific Caprico Biotechnologies 104025 CD33 PE Antibody, Clone WM53, Mouse IgG1,k, 100 Tests/Unit - 55-833LB | Genesee Scientific](https://geneseesci.com/productimages_new/55-833L.webp)
Caprico Biotechnologies 104025 CD33 PE Antibody, Clone WM53, Mouse IgG1,k, 100 Tests/Unit - 55-833LB | Genesee Scientific
![Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design | Journal for ImmunoTherapy of Cancer Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/9/e003149/F7.large.jpg)
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design | Journal for ImmunoTherapy of Cancer
![T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia | Journal for ImmunoTherapy of Cancer T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/5/e002509/F1.large.jpg)
T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia | Journal for ImmunoTherapy of Cancer
![Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design | Journal for ImmunoTherapy of Cancer Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/9/e003149/F4.large.jpg)
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design | Journal for ImmunoTherapy of Cancer
![CD33 Monoclonal Antibody (HIM3-4), FITC, eBioscience™, Invitrogen™ 100 Tests; FITC Primary Antibodies CD31 to CD35 | Fisher Scientific CD33 Monoclonal Antibody (HIM3-4), FITC, eBioscience™, Invitrogen™ 100 Tests; FITC Primary Antibodies CD31 to CD35 | Fisher Scientific](https://assets.fishersci.com/TFS-Assets/LSG/figures/11-0339-42_CD33_Flow_1-20170119083539.jpg-650.jpg)
CD33 Monoclonal Antibody (HIM3-4), FITC, eBioscience™, Invitrogen™ 100 Tests; FITC Primary Antibodies CD31 to CD35 | Fisher Scientific
![Caprico Biotechnologies 104001 CD33 Unconjugated Antibody, Clone WM53, Mouse IgG1,k, 100ug/Unit - 55-833U | Genesee Scientific Caprico Biotechnologies 104001 CD33 Unconjugated Antibody, Clone WM53, Mouse IgG1,k, 100ug/Unit - 55-833U | Genesee Scientific](https://geneseesci.com/productimages_new/55-833U.webp)